# US 2023/0413805 A1 · Systems, methods, compositions and solutions for perfusing an organ

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0413805 A1
- Document ID: US20230413805A1
- Status: Published application
- Kind: A1
- Application number: 18/241,286
- Filed: 2023-09-01
- Published: 2023-12-28
- Earliest claimed: 2005-06-28
- Assignees: Transmedics, Inc.
- Applicants: TransMedics, Inc.
- Inventors: Waleed H. HASSANEIN; Tamer I. KHAYAL; Paul LEZBERG
- Web page: https://patentgrep.com/patent/US20230413805A1

## CPC

- A01N 1/10: Preservation of living parts
- A01N 1/126: Physiologically active agents, e.g. antioxidants or nutrients
- A01N 1/143: for organ perfusion
- C12M 21/08: {for producing artificial tissue or for ex-vivo cultivation of tissue (prostheses A61F2/00, grafts A61L27/00)}
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}

## Abstract

The disclosure, in various embodiments, provides systems, methods, and solutions for perfusing an organ. The present application describes illustrative methods for perfusing an ex-vivo organ in a functioning state under physiological or near physiological conditions, including receiving an ex-vivo organ in an organ care system, the ex-vivo organ coupled to a perfusion circuit, infusing a solution into the system, combining the solution with a perfusion fluid to create a mixed solution, pumping the mixed solution to the ex-vivo organ, and receiving the mixed solution from the ex-vivo organ.

## Claims

### Claim 1

A method for perfusing an ex-vivo heart, the method comprising:
receiving an ex-vivo heart in an organ care system, wherein the ex-vivo heart is coupled to a perfusion circuit;
receiving a first solution in a first chamber of the organ care system;
receiving a second solution in a second chamber of the organ care system;
infusing, into a first fluid line in fluid communication with the first chamber and the second chamber, the first solution and the second solution;
combining, in a second fluid line of the perfusion circuit, the first solution and the second solution with a perfusion fluid to create a mixed solution; and
circulating the mixed solution through the perfusion circuit, the circulating comprising:
pumping, via the second fluid line of the perfusion circuit, the mixed solution to the ex-vivo heart; and
receiving, in a third fluid line of the perfusion circuit, the mixed solution from the ex-vivo heart.

### Claim 2 (depends on 1)

The method of claim 1, comprising:
receiving a priming solution in the perfusion circuit.

### Claim 3 (depends on 2)

The method of claim 2, wherein the priming solution comprises mannitol, sodium chloride, potassium chloride, magnesium sulfate heptahydrate, and sodium glycerophosphate.

### Claim 4 (depends on 2)

The method of claim 2, comprising:
combining the priming solution with the perfusion fluid.

### Claim 5 (depends on 4)

The method of claim 4, wherein the perfusion fluid comprises whole blood or synthetic blood.

### Claim 6 (depends on 5)

The method of claim 5, comprising:
at least partially depleting the whole blood of leukocytes or platelets before combining the perfusion fluid with the at least one of the first solution, the second solution, or the priming solution.

### Claim 7 (depends on 2)

The method of claim 2, comprising:
circulating the priming solution through the perfusion circuit in a forward flow direction.

### Claim 8 (depends on 2)

The method of claim 2, comprising:
circulating the priming solution through the perfusion circuit in a retrograde flow direction.

### Claim 9 (depends on 1)

The method of claim 1, wherein one of at least the first solution or the second solution comprises:
one or more cardio stimulants comprising a catecholamine, a peptide, a polypeptide, a β1/β2-adrenoreceptor blocking agent, bupranolol, pindolol, alprenolol, a cardiac glycoside, digitalis, palustrin, or ferulic acid;
a plurality of amino acids selected from the group consisting of alanine, arginine, aspartic acid, glutamic acid, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and lysine that do not include asparagine, glutamine, and cysteine; and
one or more electrolytes.

### Claim 10 (depends on 1)

The method of claim 1, comprising:
receiving a composition or a third solution comprising a component sensitive to sterilization in at least one of the first solution or the second solution after at least one of the first solution or the second solution has been sterilized.

### Claim 11 (depends on 10)

The method of claim 10, wherein the component sensitive to sterilization comprises insulin.

### Claim 12 (depends on 10)

The method of claim 10, wherein the at least one of the first solution or the second solution receives the composition or the third solution via a fourth fluid line.

### Claim 13 (depends on 1)

The method of claim 1, comprising:
infusing the first solution or the second solution into the perfusion circuit at a rate of between about 10 mL/hr to about 40 mL/hr.

### Claim 14 (depends on 13)

The method of claim 13, comprising:
infusing the first solution or the second solution into the perfusion circuit at a rate of about 30 mL/hr.

### Claim 15 (depends on 13)

The method of claim 13, comprising:
infusing the first solution into the perfusion circuit at a first rate; and
infusing the second solution into the perfusion circuit at a second rate different from the first rate.

### Claim 16 (depends on 1)

The method of claim 1, comprising:
circulating the mixed solution through the perfusion circuit at a rate of about 1 L/min.

### Claim 17

A method comprising:
receiving an ex-vivo organ in an organ care system, wherein the ex-vivo organ is coupled to a perfusion circuit;
receiving a first solution in a first chamber of the organ care system;
receiving a second solution in a second chamber of the organ care system;
infusing, into the perfusion circuit, the first solution and the second solution at a rate of between about 10 mL/hr to about 40 mL/hour, wherein after the infusing, the first solution and the second solution are combined with the perfusion fluid to create a mixed solution; and
circulating a perfusion fluid through the perfusion circuit, wherein the circulating comprises:
pumping, via a first fluid line of the perfusion circuit, the mixed solution to the ex-vivo organ; and
receiving, in a second fluid line of the perfusion circuit, the mixed solution from the ex-vivo organ.

### Claim 18 (depends on 17)

The method of claim 17, comprising:
receiving a priming solution in the perfusion circuit.

### Claim 19 (depends on 18)

The method of claim 18, wherein the priming solution comprises mannitol, sodium chloride, potassium chloride, magnesium sulfate heptahydrate, and sodium glycerophosphate.

### Claim 20 (depends on 18)

The method of claim 18, wherein one of at least the first solution or the second solution comprises:
a plurality of amino acids comprising alanine, arginine, histidine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and lysine that do not include asparagine, glutamine, and cysteine; and
one or more electrolytes.

### Claim 21

A method for perfusing an ex-vivo organ, the method comprising:
receiving an ex-vivo organ in a chamber of an organ care system, wherein the ex-vivo organ is coupled to a perfusion circuit;
circulating a priming solution through the perfusion circuit;
after circulating the priming solution through the perfusion circuit, infusing a first solution and a second solution into the perfusion circuit at a rate of between about 10 mL/hr to about 40 mL/hour, wherein after the infusing, the first solution and the second solution are combined with the perfusion fluid to create a mixed solution; and
circulating a perfusion fluid through the perfusion circuit at a rate of between about 1 L/min and about 5 L/min.

### Claim 22 (depends on 21)

The method of claim 21, comprising:
circulating the priming solution through the perfusion circuit in a forward flow direction.

### Claim 23 (depends on 21)

The method of claim 21, comprising:
circulating the priming solution through the perfusion circuit in a retrograde flow direction.

### Claim 24 (depends on 21)

The method of claim 21, comprising:
infusing the first solution into the perfusion circuit at a first rate; and
infusing the second solution into the perfusion circuit at a second rate different from the first rate.

### Claim 25 (depends on 21)

The method of claim 21, comprising:
infusing the first solution or the second solution into the perfusion circuit at a rate of about 30 mL/hr.

### Claim 26 (depends on 21)

The method of claim 21, wherein the priming solution comprises mannitol, sodium chloride, potassium chloride, magnesium sulfate heptahydrate, and sodium glycerophosphate.

### Claim 27 (depends on 21)

The method of claim 21, wherein one of at least the first solution or the second solution comprises:
one or more cardio stimulants comprising a catecholamine, a peptide, a polypeptide, a β1/β2-adrenoreceptor blocking agent, bupranolol, pindolol, alprenolol, a cardiac glycoside, digitalis, palustrin, and ferulic acid;
a plurality of amino acids selected from the group comprising alanine, arginine, aspartic acid, glutamic acid, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and lysine that do not include asparagine, glutamine, and cysteine; and
one or more electrolytes.
